Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Stereoselective Metabolism of Cibenzoline, an Antiarrhythmic Drug, by Human and Rat Liver Microsomes: Possible Involvement of CYP2D and CYP3A

Toshiro Niwa, Toshifumi Shiraga, Yasuyuki Mitani, Masato Terakawa, Yoji Tokuma and Akira Kagayama
Drug Metabolism and Disposition September 2000, 28 (9) 1128-1134;
Toshiro Niwa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshifumi Shiraga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuyuki Mitani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Terakawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoji Tokuma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Kagayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Stereoselective metabolism of cibenzoline succinate, an oral antiarrhythmic drug, was investigated on hepatic microsomes from humans and rats and microsomes from cells expressing human cytochrome P450s (CYPs). Four main metabolites, M1 (p-hydroxycibenzoline), M2 (4,5-dehydrocibenzoline), and unknown metabolites M3 and M4, were formed by human and rat liver microsomes. The intrinsic clearance (CLint) of the M1 formation from R(+)-cibenzoline was 23-fold greater than that of S(−)-cibenzoline in human liver microsomes, whereas the R(+)/S(−)-enantiomer ratio of CLint for M2, M3, and M4 formation was 0.39 to 0.83. The total CLint for the formation of the four main metabolites from S(−)- and R(+)-cibenzoline was 1.47 and 1.64 μl/min/mg, respectively, suggesting that the total CLint in R(+)-enantiomer was slightly greater than that in S(−)-enantiomer in human liver microsomes. The M1 formation from R(+)-cibenzoline was highly correlated with bufuralol 1′-hydroxylation and CYP2D6 content and was inhibited by quinidine, a potent inhibitor of CYP2D6. Additionally, only microsomes containing recombinant CYP2D6 were capable of M1 formation. These results suggest that the M1 formation from R(+)-cibenzoline was catalyzed by CYP2D6. The formation of M2, M3, and M4 from S(−)- andR(+)-cibenzoline was highly correlated with testosterone 6β-hydroxylation and CYP3A4 content. Ketoconazole, which is a potent inhibitor of CYP3A4/5, had a strong inhibitory effect on their formation, and the M4 formation from R(+)-cibenzoline was inhibited by quinidine by 45%. The formation of M2 was also inhibited by quinidine by 46 to 52% at lower cibenzoline enantiomers (5 μM), whereas the inhibition by quinidine was not observed at a higher substrate concentration (100 μM). In male rat liver microsomes, ketoconazole and quinidine inhibited the formation of the main metabolites, M1 and M3, >74% and 44 to 59%, respectively. These results provide evidence that CYP3A and CYP2D play a major role in the stereoselective metabolism of cibenzoline in humans and male rats.

Footnotes

  • Send reprint requests to: Dr. Toshiro Niwa, Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Kashima 2-1-6, Yodogawa-ku, Osaka 532-8514, Japan. E-mail: toshiro-niwa{at}po.fujisawa.co.jp

  • Abbreviations used are::
    CYP
    cytochrome P450
    FMO
    flavin-containing monooxygenases
    G6P
    glucose-6-phosphate
    G6PDH
    glucose-6-phosphate dehydrogenase
    PB
    phenobarbital sodium
    BNF
    β-naphthoflavone
    DEX
    dexamethazone
    CLO
    clofibrate
    CLint
    intrinsic clearance
    CL
    total clearance
    • Received February 28, 2000.
    • Accepted May 25, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 28 (9)
Drug Metabolism and Disposition
Vol. 28, Issue 9
1 Sep 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stereoselective Metabolism of Cibenzoline, an Antiarrhythmic Drug, by Human and Rat Liver Microsomes: Possible Involvement of CYP2D and CYP3A
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Stereoselective Metabolism of Cibenzoline, an Antiarrhythmic Drug, by Human and Rat Liver Microsomes: Possible Involvement of CYP2D and CYP3A

Toshiro Niwa, Toshifumi Shiraga, Yasuyuki Mitani, Masato Terakawa, Yoji Tokuma and Akira Kagayama
Drug Metabolism and Disposition September 1, 2000, 28 (9) 1128-1134;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Stereoselective Metabolism of Cibenzoline, an Antiarrhythmic Drug, by Human and Rat Liver Microsomes: Possible Involvement of CYP2D and CYP3A

Toshiro Niwa, Toshifumi Shiraga, Yasuyuki Mitani, Masato Terakawa, Yoji Tokuma and Akira Kagayama
Drug Metabolism and Disposition September 1, 2000, 28 (9) 1128-1134;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics